NASDAQ: FENC

Fennec Pharmaceuticals Inc.

Healthcare | Biotechnology

No licensed closing price on file for FENC. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (FY2025)$-0.34

Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-21 11:08 UTC.

What Fennec Pharmaceuticals Inc. does

Fennec Pharmaceuticals develops and commercializes PEDMARK, a sodium thiosulfate injection product protected by multiple patents listed in the FDA Orange Book. The company has faced patent challenges from generic competitor Cipla, including Paragraph IV Certifications on three patents, which led to litigation settled in March 2026 under terms preventing Cipla market entry until September 1, 2033.

Summarized from Fennec Pharmaceuticals Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation	8-K 2026-06-10
EPS (FY2025)	$-0.34

Revenue, margins & earnings

Net income
Taxes & interest
Operating costs
Net loss year

Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-13

2026-10-13Chief Executive OfficerAward2,224$12.3K
2026-10-13Chief Medical OfficerAward3,846$21.3K
2026-10-13Chief Commercial OfficerAward2,326$12.9K

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

Rosalind Advisors, Inc.3,188,001$34.27M+9.6%
AIGH Capital Management LLC2,486,038$26.72M+25.5%
Solas Capital Management, LLC1,889,366$20.31M-23.9%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2026-04-28Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2024-10-30Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersTerry EvansEstimatedSEC 8-K →
2024-08-07Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

No qualifying company news in the archive. Full tape in the platform →

Questions this page answers

What does Fennec Pharmaceuticals Inc. do?

Fennec Pharmaceuticals develops and commercializes PEDMARK, a sodium thiosulfate injection product protected by multiple patents listed in the FDA Orange Book.

When did FENC last file with the SEC?

Fennec Pharmaceuticals Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-10. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-21 11:08 UTC. This page is also available as JSON at /api/data?ticker=FENC and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for FENC and 5,000+ tickers.

Create a free account — keep FENC

For your agent

GET /api/data?ticker=FENC

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt